Physician profile
Jody E Gilstrap
NPI 1902856628
$6,015.26
in general payments reported to CMS, 2019-2025
36 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,243 · 2022: $981 · 2023: $1,198 · 2024: $1,231 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,102.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $708.02 | 2021-2025 | |
| Pfizer INC. | $498.11 | 2021-2025 | |
| Lilly USA, LLC | $475.32 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $386.62 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $337.80 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $241.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $240.31 | 2022-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.92 | 2022-2025 | Xifaxan |
| Abbott Laboratories | $225.79 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.61 | 2022-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $135.56 | 2023-2025 | Gemtesa |
| Amgen INC. | $132.49 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Astellas Pharma US INC | $125.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.83 | 2021-2023 | Trintellix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $96.44 | 2025 | Integra, Omnigraft, Surgimend |
| Phathom Pharmaceuticals, INC. | $78.02 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $73.54 | 2021-2023 | Nexletol |
| Antares Pharma, INC. | $69.76 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $67.97 | 2024-2025 | Jatenzo |
| Amarin Pharma, INC. | $62.49 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $58.86 | 2021-2025 | Contrave, Onzetra Xsail |
| Merck Sharp & Dohme LLC | $51.72 | 2021-2023 | Belsomra |
| Halozyme INC | $45.77 | 2023 | |
| Dexcom, INC. | $44.59 | 2024-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $35.89 | 2022 | |
| Lundbeck LLC | $35.42 | 2021-2023 | Rexulti |
| Dynavax Technologies Corporation | $32.14 | 2024 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $29.90 | 2021 | |
| Siemens Medical Solutions USA, INC. | $27.90 | 2025 | Immulite 1000 Immunoassay System |
| Biogen, INC. | $22.18 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.65 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2021 | |
| Linus Health, INC. | $11.42 | 2024 | Core Cognitive Evaluation |
| Axsome Therapeutics, INC. | $9.64 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Gilstrap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.